The very same molecular mechanism was implicated in the negative effect of Rocaglamide A on ERK pathway activity in KRAS-driven lung cancer (46), although the picture might be somewhat complicated by the finding that KRAS oncogene expression could be eIF4F-dependent, at least in some tumor types (47). This evidence concerns the gene KRAS and neoplasm.